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Introduction. To determine the value of a FDG-PET-CT scan in patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) prior to chemoradiotherapy. Materials and Methods. Consecutive patients with stage III or IV HNSCC who
had undergone a staging FDG-PET-CT scan prior to chemoradiotherapy between August 2008 and April 2011 were included.
Clinical details and conventional imaging (CT and/or MRI) were, retrospectively, reviewed, a TNM stage was assigned, and levels
of cervical lymph node involvement were documented. This process was repeated with the addition of FDG-PET-CT. Radiotherapy
plans were reviewed for patients with an alteration identified on TNM staging and/or nodal level identification with FDG-PET-CT
and potential alterations in radiotherapy planning were documented. Results. 55 patients were included in the analysis. FDG-
PET-CT altered the TNM stage in 17/55 (31%) of patients, upstaging disease in 11 (20%) and downstaging in 6 (11%); distant
metastases were identified by FDG-PET-CT in 1 (2%) patient. FDG-PET-CT altered the lymph node levels identified in 22 patients
(40%), upclassifying disease in 16 (29%) and downclassifying in 6 (11%). Radiotherapy plans were judged retrospectively to have
been altered by FDG-PET-CT in 10 patients (18%).Conclusions. The use of FDG-PET-CT potentially impacts upon both treatment
decisions and radiotherapy planning.
1. Introduction
Locoregional staging for head and neck squamous cell
carcinoma (HNSCC) is performed using a combination of
clinical examination, examination under anaesthetic and
crosssectional imaging with computed tomography (CT)
and/or magnetic resonance imaging (MRI). Anatomical
imaging is fundamentally limited for detection of malig-
nancy in nonnecrotic lymph nodes which fall below standard
size criteria for example, short axis diameter of 10mm [1].
This is illustrated by the finding that only micrometastases
of less than 3mm were present in 25% of pathologically
proven tumour-positive neck dissections [1]. An ultrasound
study has suggested that a cutoﬀ of 6mm may be the optimal
compromise between sensitivity and specificity for cervical
lymph nodes [2]. The risk of lymph node metastases is
dependant upon tumour site, extent, and lateralisation [3].
The sensitivity and specificity of CT and MRI have been esti-
mated at 50–80% and 70–90%, respectively [4, 5]. The failure
of conventional staging to detect disease in the clinically node
negative neck (cN0) is recognised in treatment protocols by
the incorporation of prophylactic therapy to the neck with
either a neck dissection or radiotherapy when the risk of
nodal metastases is expected to exceed 20% [6].
In the modern era, organ preserving nonsurgical radio-
therapy-based approaches to the management of locally
advanced HNSCC are increasingly employed [7]. Treatment-
related late morbidity can be substantial [8]. The intensity-
modulated radiotherapy (IMRT) technique utilises multiple
radiation beams of nonuniform intensity derived from
inverse planning and is now in routine clinical practice
for HNSCC [9]. IMRT allows radiotherapy doses to be
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accurately delivered with steep dose gradients and lower
doses to areas deemed to be at lower risk and minimal dose
to other organs. The ability of IMRT to deliver doses with a
high degree of conformality has led to interest in the use of
IMRT to successfully eliminate sites of tumour involvement
whilst sparing normal tissues [10, 11]. Appropriate patient
selection and accurate target definition are critical to the
success of attempts to spare normal tissues, with the potential
for the risk of increased nodal recurrence associated with
the steep dose gradients in IMRT [12]. Indeed, quality
of radiotherapy has been identified as a major factor in
determining outcome of nonsurgical treatment for HNSCC
[13]. Reliable localisation of sites of tumour involvement
is essential to the success of treatment protocols aimed at
limiting late tissue toxicity.
The radiation oncologist frequently has to make diﬃcult
judgements based on anatomical imaging to include or
otherwise equivocal lymph nodes in the high-dose target
volume. Functional imaging techniques oﬀer the potential to
provide complementary information to anatomical imaging
with CT and MRI to aid in these decisions. 18Fluoride-fluor-
odeoxyglucose positron emission tomography (FDG PET)
is a widely used functional imaging technique in oncology.
Tumour cells exhibit diﬀerential glucose uptake (the “War-
burg eﬀect”) as a basis of the identification of cancer [14].
Increased glucose uptake by nonmalignant tissue, common-
ly in the presence of infection or inflammation, leads to
false positive results. Integrated PET-CT, which combines the
complementary techniques of PET and CT in a single study,
oﬀers the potential to improve upon the inherent size limita-
tions in terms of accurate lymph node identification with
MRI and CT, not being limited by formal size criteria
[15]. Limitations of PET include issues with regard to scan-
ner resolution, partial volume eﬀects, and the need for accu-
rate coregistration with the CT scan. FDG PET-CT imag-
ing in HNSCC has multiple potential applications including
staging, radiotherapy planning, treatment adaptation, res-
ponse assessment, and recurrence detection [9, 15, 16]. The
site of recurrence has been shown to correlate with the base-
line sites of FDG-avid disease [17]. FDG PET-CT has been
demonstrated to be able to identify metastatic head and neck
malignancy in cases where MRI and CT fail to demonstrate
disease [18, 19]. The use of FDG PET-CT for staging HNSCC
(other than in the setting of cervical lymph node metastases
of unknown primary origin) remains controversial, with
some authorities not recommending its use in routine stag-
ing [9], whilst others support the role of FDG PET-CT for
staging locoregional and distant disease [20]. Some studies
have suggested that the addition of FDG PET-CT to con-
ventional staging methods improves the accuracy of nodal
assessment [21–23]. At the heart of any debate regarding the
utility of FDG PET-CT in addition to conventional anato-
mical imaging is the assessment of the potential impact of the
investigation upon patient management. This impact may
vary depending upon the patient population, tumour stage,
and treatment under consideration.
The aim of this study was to assess the utility of FDG
PET-CT as an adjunct to conventional staging methods
in patients with locally advanced HNSCC due to undergo
primary nonsurgical treatment. The value of FDG PET-CT
on identification of levels of nodal involvement was deter-
mined to assess whether FDG PET-CT can influence process
of defining the radiotherapy target volume.
2. Methods
2.1. Inclusion Criteria. Formal institutional review board ap-
proval was waived for this retrospective study. Consecutive
patients between August 2008 and April 2011 who under-
went a FDG PET-CT scan for head and neck cancer were
obtained from an institutional database. Electronic case
notes were used to identify patients who fulfilled the eligibi-
lity criteria for the study.
Eligible patients fulfilled all of the following criteria.
(1) Histologically confirmed squamous cell carcinoma of
the oropharynx, oral cavity, hypopharynx, larynx, or
paranasal sinuses.
(2) Nasopharyngeal cancer was excluded.
(3) Reviewed by specialist head and neck multidisciplin-
ary meeting.
(4) TNM stage III or IV prior to FDG PET-CT scan.
(5) Decisionmade prior to FDG PET-CT to proceed with
radical nonsurgical treatment (radiotherapy alone or
chemoradiotherapy).
(6) FDG PET-CT performed prior to commencement of
treatment for staging and/or as a baseline for future
response assessment.
Baseline demographics were obtained from review of elec-
tronic case notes (Patient Pathway Manager, Leeds).
2.2. Staging. Conventional staging of locally advanced
HNSCC was routinely performed by physical examination
and neck palpation, fiberoptic endoscopy, examination un-
der anaesthetic with biopsy where indicated, MRI or contra-
st-enhanced CT of head and neck region depending upon
local protocols, and CT of the thorax. Results were routinely
reviewed in a specialist head and neck MDT meeting and a
TNM classification, based on all available clinical and radio-
logical data, according to the American Joint Committee on
Cancer TNM staging was assigned prior to the FDG PET-CT
scan [24]. The method of conventional crosssectional imag-
ing used for staging was recorded from radiology records.
2.3. CT Protocol. Contrast-enhanced CT was most com-
monly performed at our institution after referral from the re-
gional oncology team on a 64-slice CT (Siemens Sensation,
Siemens Healthcare, Erlangen, Germany) using a contiguous
1mm reconstruction following a bolus of 100mL of iodi-
nated contrast or a 16-slice CT (Siemens 16, Siemens Health-
care) using the same acquisition parameters. The remaining
contrast-enhanced CT scans were acquired at one of several
referring hospitals on multislice CT systems using similar ac-
quisition parameters.
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2.4. MRI Protocol. MRI examinations of the head and neck
were most commonly performed at our institution using 1.5-
Tesla systems (Symphony/Avanto; Siemens, Erlangen, Ger-
many). Scan limits were skull base to clavicles. Standard seq-
uences included axial and coronal T1, axial T2 (fat sat) and
coronal STIR, and axial and coronal T1 post-Gadolinium.
Sagittal T1 post-Gadolinium was performed for tongue base
tumours.
2.5. FDG PET-CT Protocol. FDG PET-CT examinations pri-
or to June 2010 were performed on a 16-slice Discovery STE
PET-CT scanner (GE Healthcare, Amersham, UK) and from
June 2010 on a 64-slice Philips Gemini TF64 scanner (Phi-
lips Healthcare, Netherlands). PET acquisition from skull
vertex to upper thighs was performed 60 minutes after a
400MBq dose of intravenous 18F-FDG. A silence protocol
was employed in the uptake period following tracer injection
to minimise physiological tracer activity within the head and
neck region. The CT component was performed according
to a standardised protocol (without the use of iodinated con-
trast medium) with the following settings: 140 kV; 80 mAs;
tube rotation time 0.5 s per rotation; pitch 6; section thick-
ness 3.75mm (to match the PET section thickness). Patients
maintained normal shallow respiration during the CT acqui-
sition. Images were reconstructed using a standard OSEM
algorithm with CT for attenuation correction. Both non-
attenuation corrected and attenuation corrected datasets
were reconstructed.
2.6. Review of Imaging Investigations. Imaging for each pa-
tient was retrieved from the institutional picture archiving
and communications system (PACS)(IMPAX, AGFA Health-
care, Mortsel, Belgium). PET-CT imaging was reviewed on
a specialised PET-CT workstation (XD3, Mirada-Medical,
Oxford, UK). Imaging was retrospectively reviewed by two
experienced radiologists independently. Visual interpreta-
tion was qualitative, with regions with an FDG uptake above
background mediastinal blood pool classed as positive. Any
discrepancies were discussed in order to reach a consensus
view. Clinical information and MRI and/or CT scans were
reviewed by the same radiologists in conjunction with radiol-
ogy reports. Standard size criteria [1] were used to determine
lymph node involvement on CT and MRI imaging. Levels
of lymph node involvement were documented. This study
was intended to determine the incremental rather than inde-
pendent value of FDG PET-CT. AJCC TNM classification
was recorded based upon assessment of the FDG PET-CT
scan in conjunction with other prior imaging and clinical
information. In the same manner, involved lymph node
levels were documented.
Based upon this data, any alterations in the TNM stage
and/or levels of lymph node involvement between conven-
tional imaging and PET-CT were documented.
2.7. Clinical Impact
2.7.1. Impact upon Treatment Modality/Intent. Management
plan prior to FDG PET-CT staging was determined from
electronic case notes and MDT records. Alterations in treat-
ment modality/intent of treatment following FDG PET-CT
were determined by retrospective review of records.
2.7.2. Impact upon Radiotherapy Planning. During the early
part of the study period, patients were treated with a
conformal technique involving a parallel opposed pair [25];
this technique would not allow nodal levels within the
high-dose volume to receive diﬀerent doses. IMRT was
subsequently implemented into routine clinical practice,
facilitating the treatment of diﬀerent lymph node levels with
diﬀerent doses. Institutional protocols were followed with a
radical treatment dose of 70Gy in 35 fractions over 7 weeks,
with lower doses to prophylactic dose regions (54–63Gy in
35 fractions over 7 weeks).
In general, using either technique, gross tumour volume
was included within the high-dose volume, and areas deemed
to be at lower risk were treated with prophylactic doses. In
patients in whom a discrepancy was noted between the TNM
staging and/or lymph node level identification, radiotherapy
plans were reviewed to determine whether the lymph node
was included in high-dose or prophylactic dose regions. A
retrospective qualitative judgement was made as to whether
FDG PET-CT altered had no impact or was ignored during
the radiotherapy planning process. This was assessed by
two experienced clinical oncologists independently, and any
disagreements were discussed in order to reach a consensus
view.
2.8. Statistics. Baseline characteristics and radiological find-
ings were summarised using descriptive statistics.
3. Results
55 patients were eligible for inclusion in the study. Median
age was 55 (range 28–75). 42/55 (76%) were male. Smoking,
alcohol history, and performance status were recorded in
54 patients; 23 were current smokers, 10 exsmokers, and
21 had never smoked. 13 were classed as having a heavy
alcohol intake (at least 50 units/week), 36 drank some alcohol
(<50 units/week), and 5 did not drink alcohol. World Health
Association (WHO) performance status was recorded in 54
patients:WHOPS 0,1,2 in 31, 16, and 7 patients, respectively.
Tumour site, subsite, stage prior to FDG PET-CT, his-
tology, and intended management plan prior to FDG PET-
CT are shown in Table 1. The TNM distribution is shown
in Table 2. 12 patients were conventionally staged with both
MRI and CT examinations, 33 were staged with MRI alone,
and 10 with a CT alone, in addition to clinical examination.
3.1. TNM Staging Changes Resulting From FDG PET-CT
Examination. The median time between CT or MRI staging
of the head and neck and the FDG PET-CT scan was
17.5 days (range 4–42). The median maximum SUV of the
primary tumour was 13.1 (range 5.3–44) and for lymph
nodes 8.7 (range 5.3-44). TNM stage at FDG PET-CT was
discordant with staging utilising clinical information and CT
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Table 1: Disease site, subsite, stage, histology, and intended
treatment prior to PET-CT examination.
Characteristic
Number
(%)
Oropharynx
Tonsil
Base of tongue
Posterior pharyngeal wall
47 (85%)
25
21
1
Hypopharynx
Pyriform fossa
4 (7%)
4
Larynx
Supraglottis
2 (4%)
2
Paranasal sinus 1 (2%)
Oral cavity
Retromolar trigone
1 (2%)
1
Stage
III
IV
14 (25%)
41 (75%)
Histology
SCC
Poorly diﬀerentiated
Moderately diﬀerentiated
Well diﬀerentiated
Not classified
55 (100%)
29 (53%)
18 (33%)
0 (0%)
8 (15%)
Intended treatment
Radical radiotherapy 12 (22%)
Concurrent chemoradiotherapy 36 (65%)
Induction + concurrent chemoradiotherapy 6 (11%)
Concurrent cetuximab and radiotherapy 1 (2%)
Table 2: TNM distribution prior to PET-CT examination.
T1 T2 T3 T4
N0 4 2 6
N1 4 5 1 1 11
N2a 2 0 0 0 2
N2b 6 8 2 5 21
N2c 2 6 2 4 14
N3 1 0 0 0 1
15 19 9 12 55
and/or MRI in 17 (31%) of patients. The changes are sum-
marised in Table 3. In one patient with locally advanced ton-
sil cancer, CT thorax demonstrated 5 small (sub-5mm) inde-
terminate lung nodules. PET-CT demonstrated FDG uptake
in the pulmonary nodules and identifying a contralateral
retropharyngeal lymph node; TNM classification was there-
fore altered from T4N2bMx to T4N2cM1. All other changes
to TNM classification were within the nodal classification.
3.2. Changes in Identification of Lymph Node Involvement
Resulting from FDG PET-CT Examination. The involvement
of neck lymph node levels was determined utilising clinical
information and CT and/or MRI imaging. There was dis-
cordance in lymph node level involvement on FDG PET-CT
Table 3: Summary of TNM alterations following PET-CT.
Eﬀect of PET-CT on TNM No. of patients
Upstaging 11 (20%)
N0 to N1
N0 to N2b
N0 to N2c
N1 to N2c
N2a to N2b
N2b to N2c
M0 to M1
1
1
2
1
1
4
1
Downstaging 6 (11%)
N1 to N0
N2c to N2a
N2c to N2b
1
1
4
No impact 38 (69%)
and conventional imaging in 22 of 55 (40%) patients (Sum-
marised in Table 4). An example in which FDG uptake
was detected in an additional subcentimetre lymph node
altering TNM staging and lymph node level identification is
shown in Figure 1. Alterations of nodal staging included both
upstaging and downstaging. Histological correlation was not
performed on these patients.
3.3. Upstaging. In 16 patients, FDG PET-CT suggested
involvement of an additional lymph node level not identified
on other imaging. In 5 of these cases, PET-CT detected FDG-
positive contralateral lymph nodes, where no contralateral
nodal involvement had been previously demonstrated. In
3 cases, PET-CT showed FDG uptake suggestive of nodal
involvement in what had been classed as an N0 neck.
3.4. Downstaging. In 6 patients FDG PET-CT downclassified
possible lymph node involvement on anatomical imaging
on the basis of a lack of FDG avidity. In each of these
cases, nonnecrotic lymph nodes identified on the staging
CT and/or MRI were regarded as equivocal based upon size
criteria. In 5 of these 6 cases, the FDG PET-CT findings
altered the staging of an N2c neck to unilateral nodal
disease. In the remaining case, an equivocal lymph node was
downclassified to an N0 stage.
3.5. Impact of FDG PET-CT Findings on Clinical Manage-
ment. The treatment intention was altered in 1 of 55 patients
following FDG PET-CT. This patient, as discussed above, had
small indeterminate lung nodules on CT. The demonstration
that these were highly likely to be metastatic on FDG
PET-CT led to the patient being oﬀered palliative rather
than radical radiotherapy. Further clinical and imaging
followup is awaited on this patient. There were no alterations
in treatment modality as a result of FDG PET-CT. One
patient altered his treatment decision and opted for surgery
opposed to nonsurgical treatment. Two patients were treated
with palliative rather than radical radiotherapy due to a
deteriorating performance status and patient preference.
In one of these patients FDG PET-CT had altered nodal
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Table 4: Summary of alterations in lymph node level involvement based on PET-CT (n = 22).
Lymph node levels identified on
clinical staging, MRI, and/or CT
Lymph node levels identified on
PET-CT in combination with
clinical staging, MRI, and/or CT
Alteration due to PET-CT
1 Right II None Downclassified equivocal LN
2 Left II, III, Right II Left II, III Downclassified equivocal contralateral level II LN
3 Left II, III Left II, III, V Identified sub-cm LN level V
4 Right II Right II, III Identified sub-cm LN level III
5 Left II, III, IV Left II, III, IV, Right II Identified contralateral 1 cm LN
6 Left II, Right II Left II Downclassified equivocal contralateral R II
7 None RP Identified RP involvement
8 Left II, IV Left Ib, II, IV Identified 1 cm LN level 1b
9 None Right II, III. Left II, III Identified bilat LN subcm
10 Left II, IV Left II, III, IV Identified 12mm LN level III
11 Left II, III, IV, V, Right II Left II, III, IV, V Downclassified equivocal contralateral II
12 Right 1b-V Right 1b-V, Left II Identified equivocal contralateral level II
13 Right II, Left II Right II Downstages equivocal contralateral II
14 Right Ib, II, III Left Ib, II, III Left II Downstaged multiple equivocal LN
15 None Right II, Left III Identified sub-cm bilateral LN
16 None Right III Identified 2 sub-cm LN in level III
17 Right III Right II, III Identified 2 LN (1 cm) in level II
18 Right II, Left II, III Right II, III, Left II, III, RP Identified sub-cm LN level III and 13mm RP LN
19 Right III Right III, Left III Identified 1 cm contralateral Level III
20 Left II, III, IV Right II, left II, III, IV Identified 1 cm contralateral level II
21 Right II, Left II Right II, Left 1b, II Identified 7mm Ib
22 Right II, III, V Right II, III, IV, V, Left RP Identified sub-cm level IV and contralateral RP
(a) (b) (c)
Figure 1: Altered TNM staging and lymph node level identification with FDG PET-CT. T4 squamous cell carcinoma of left tonsil. Diagnostic
CT identified T4 N2b disease. FDG PET-CT identified a subcentimetre (SUVmax = 3.5) contralateral lymph node, altering staging to T4 N2c.
(a) Diagnostic contrast-enhanced CT. (b) Coregistered FDG PET-CT. (c) FDG PET. White arrow = right level II lymph node.
stage from N2a to N2b although no additional lymph node
levels were identified. The 52 remaining patients all received
the radical nonsurgical treatment modality that had been
proposed prior to the FDG PET-CT.
The radical radiotherapy treatment plans of patients with
an alteration in involved neck lymph node levels based on
FDG PET-CT (Table 4), excluding patient 18 who was the
patient who opted for surgical treatment and patient 22 who
had probable lung metastases were retrospectively reviewed
to ascertain the impact of FDG PET-CT upon radiotherapy
planning (Table 5). 17 of these 20 patients were treated with
an IMRT technique, one with unilateral conformal technique
and two with a conformal parallel opposed pair.
In the 6 patients with equivocal lymph nodes on
conventional imaging which were FDG negative, one patient
received unilateral radiotherapy as a result of the FDG PET-
CT findings; 2 patients were treated only with prophylactic
doses. In these 3 patients, FDG PET-CT was deemed to have
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Table 5: Impact of PET-CT upon radiotherapy planning in patients
with altered identification of involved lymph node levels (n = 20).
No of patients
PET-CT downclassified lymph node levels: 6
Lymph node not treated that is unilateral
radiotherapy
1
Lymph node in prophylactic dose region 2
In high-dose region 2
Parallel opposed pair hence lymph node in
high-dose region
1
Overall: likely plan change 3
PET-CT identified additional FDG-avid lymph
node levels:
14
Lymph node in high-dose region 11
Lymph nodal level in prophylactic dose
region
2
Parallel opposed pair hence lymph 1
node in high-dose region
Overall: likely plan change 7
altered the radiotherapy plan. One patient received a parallel
opposed pair technique, precluding any impact of the FDG
PET-CT upon the plan. In the remaining two patients, the
FDG PET-CT findings were not utilised as the FDG negative,
lymph node regions were treated in the high-dose volume.
In the 14 patients in whom FDG PET-CT identified addi-
tional lymph node levels, these nodal levels were included in
the high-dose volume in 11 cases. An example of a high-dose
clinical target volume including the FDG avid lymph node
is shown in Figure 2. A subjective judgement was made that
the plan had been altered by FDG PET-CT in 7 of these cases.
In 2 cases, the FDG PET-CT findings were not utilised, with
FDG avid nodal areas treated to prophylactic doses. In both
of these cases identified lymph nodes were subcentimetre in
size and showed only mild FDG uptake.
FDG PET-CT demonstrated FDG avid axillary lymph
nodes in 2 patients (SUV 6.7 in a 10mm lymph node in one
patient and an SUV of 5.4 in a 17mm lymph node in the sec-
ond patient). In both cases ultrasound-guided biopsies dem-
onstrated reactive changes only, and there has been no cli-
nical progression of the axillary lymph node after clinical
followup of 14 and 8months, respectively. Therefore, in these
2 cases, FDG PET-CT generated a false positive result out-
side of the head and neck region that had required further in-
vestigation.
4. Discussion
Advances in the ability to accurately identify all sites of dis-
ease underpin attempts to improve radiotherapy outcomes
for HNSCC. Purely anatomical imaging with CT and MRI is
inherently limited in failing to detect nonenlarged malignant
lymph nodes. Functional imaging techniques, such as inte-
grated FDGPET-CT, are not limited in the samemanner, and
their incorporation into existing staging protocols is highly
attractive. FDG PET-CT could be used in the radiotherapy
planning process to identify the target lymph nodes and/or
to be used to contour target tissue. The delineation of target
lymph nodes using FDG PET is highly dependent upon the
methodology of PET segmentation which remains highly
controversial [26, 27].
Evidence with regard to the ability of FDG PET-CT to
improve upon the staging of cervical lymph node levels is
based upon multiple retrospective and prospective series.
Kyzas et al. [28] performed a meta-analysis in which 32 stud-
ies with 1236 cases were included with histological verifica-
tion to attempt to determine the ability of FDG PET-CT to
evaluate cervical metastases in HNSCC. Within this meta-
analysis, FDG PET had a sensitivity of 79% (95% CI 72–
85%) and a specificity of 86% (95% CI 83–89%). Notably,
FDG PET only had a sensitivity of 50% (95% CI 37–63%)
in the N0 neck. In an attempt to compare these results with
conventional imaging, a subanalysis was performed on stud-
ies in which both FDG PET and conventional tests were per-
formed. In these studies, FDG PET had a sensitivity and
specificity of 80% and 86% versus 75% and 79% for conven-
tional imaging alone. Therefore, FDG PET appears to oﬀer a
modest improvement in the neck staging accuracy. Further-
more, in clinical practice the important question is not
CT/MRI versus FDG PET-CT, but rather determining what
is the incremental benefit of PET-CT in addition to routine
imaging including CT/MRI [15]. Kubicek et al. [29] retro-
spectively reviewed 212 PET scans of patients who went on
to receive radiotherapy and report high positive and negative
predictive values of 94% and 89%, respectively. The positive
and negative predictive value of the test will depend upon
the patient population to which it is applied. For example
the value of FDG PET-CT in identifying an additional nodal
level in an N+ neck to assist radiotherapy planning is likely to
be diﬀerent to the situation in anN0 neck. The ability of FDG
PET-CT to stage an N0 neck is currently under investigation
in a prospective USA study with pathological correlation,
ACRIN 6685 [30].
A series of studies have explored whether the use of
FDG PET-CT has any impact upon clinical management
of HNSCC. Several series have now demonstrated the im-
pact of FDG PET on management decisions [21, 31–36].
Analysis of a large retrospective series of 123 patients showed
a management change in 31% of patients [21]. In a prospe-
ctive study of 71 patients, FDG PET was reported to alter
the TNM stage in 31% of patients (this study did not in-
clude pathological validation) [31]. In the largest series, a
multicentre prospective study, Lonneux et al. [32] evaluated
the addition of FDG PET to conventional staging of HNSCC.
Out of 233 patients, FDG-PET and conventional TNM stage
were discordant in 100 patients. Histological confirmation
was available in 41 of these 100 discordant patients, with ad-
ditional imaging and clinical followup regarded as “gold-
standard” in a further 19 cases. Out of these “confirmed”
60 patients, nodal stage was accurately upgraded in 16 and
downgraded in 7. FDG PET was found to be accurate in 67%
of patients with confirmed nodal discrepancies. Of the 40 pa-
tients lacking “confirmation”, the N stage was upgraded in
28 and downgraded in 11. Therefore, nodal staging dis-
crepancies within this study were common. The study did
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(a) (b)
(c) (d)
Figure 2: Modification of radiotherapy target volume based on FDG PET-CT. T4 maxillary sinus SCC. Diagnostic CT staged at T4 N0.
FDG PET-CT identified an FDG avid (SUVmax = 12) left retropharyngeal lymph node altering staging to T4 N1. The radiotherapy clinical
target volume incorporates this lymph node. (a) Diagnostic CT. (b) Coregistered FDG PET-CT. (c) FDG PET. (d) Green line = clinical target
volume on planning CT scan including FDG avid left retropharyngeal lymph node. White arrow = FDG avid left retropharyngeal lymph
node.
not report alterations in involvement of nodal levels which
did not alter TNM staging. Overall, the study reported that
FDG PET altered patient management in 13.7% of patients;
this included the detection of distant metastases in 6 patients
and an alteration of radiotherapy fields in 8 patients.
It is important to note that within almost all of the studies
in the Kyzas et al. [28] meta-analysis and the majority of
patients in the other major series [31, 32], FDG PET was
single modality rather than integrated PET-CT, which has
subsequently been shown to have higher accuracy than FDG
PET alone [36–38].
Our series of 55 patients diﬀers from other reported
series in that a decision to proceed with primary nonsurgical
had been made prior to the FDG PET-CT scan and that
patients were restricted to stage III/IVHNSCC. FDGPET-CT
was performed both for staging and to provide a baseline for
future response assessment. In order to examine the clinical
utility of FDG PET-CT, we analysed the data to determine
the incremental change to TNM staging and alteration of
distribution of lymph node level involvement, in addition to
conventional staging. Abnormal areas of FDG avidity were
defined as being above background, as previously described
by Lonneux et al. [32]. Changes in lymph node level involve-
ment were highlighted to assess the potential consequences to
IMRT planning. The time between conventional staging and
the FDG PET-CT was short (median 17.5 days). Therefore,
disease progression between imaging studies is unlikely to
have had a significant impact.
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The main limitation of this study is that pathological
validation was not performed in any of these patients. This
has also been the case in other series [31, 33]. The majority
of patients (85%) had oropharynx primary tumours. In our
practice these patients are managed without surgical inter-
vention other than for salvage [25, 39]. Although ultrasound-
guided fine needle aspiration oﬀers the option of attempting
to confirm FDG PET-CT findings, further investigation risks
treatment delay and sampling errors especially for small
lymph nodes. With increasing experience of FDG PET-CT,
a pragmatic approach may be taken whereby histological
clarification may not always be required when the imaging
findings are categorical and give a high level of confidence
for disease involvement. Under these circumstances, invasive
sampling may be reserved for cases where the imaging
findings are more equivocal.
The retrospective nature of this study is a further poten-
tial limitation. This is minimised by the interpretation at sep-
arate sittings of both imaging and radiotherapy plans by two
radiologists and clinical oncologists, respectively. Although
there is the possibility of selection bias of patients under-
going PET-CT, the TNM distribution of these stage III/IV
patients is broadly similar to that in our previous report
of the outcome of stage III/IV tonsil cancers [25]. PET-CT
scans in this series were performed without intravenous con-
trast. However, the availability of recent contrast-enhanced
imaging with CT and/or MRI reduces the likelihood of
this significantly reducing the quality of PET-CT scan inter-
pretation.
In these 55 patients, TNM stage was altered by the FDG
PET-CT findings in 17 (31%) patients (Table 3). This is con-
sistent with alterations in TNM staging in other series: 40%
in Lonneux et al. [32], 34% in Connell et al. [33], and 31%
in Scott et al. [31]. The frequency of alteration in the identifi-
cation of levels of nodal involvement has not been reported
in other series. This has potential impact upon IMRT plann-
ing in which involved and uninvolved nodal levels will
receive diﬀerent doses. FDG PET-CT in addition to clinical
assessment and conventional anatomical imaging altered the
identification of nodal levels in 22 of 55 patients (40%)
(Table 4). In 16 of these patients, FDGPET-CT demonstrated
at least one additional nodal level, whilst in 6 patients poten-
tial nodal involvement was downstaged. The major limita-
tion in interpreting these findings is the lack of pathological
correlation. FDGPET-CT altered the interpretation of lymph
nodes which were small and largely subcentimetre in maxi-
mum diameter. In addition, some lymph nodes demon-
strated low-grade FDG uptake, and accuracy of staging may
have been improved by invasive sampling in such cases.
Whilst accepting that histological validation is absent, it is
possible to interpret these results in the light of other studies.
As discussed, Kyzas et al.[28] showed that 18FDG-PET has
a higher sensitivity and specificity for lymph node involve-
ment than CT or MRI. In the study by Lonneux et al. [32],
FDG PET had a 67% accuracy in nodes where there was a
discrepancy with conventional staging. On this basis, the use
of FDG PET-CT data in radiotherapy planning for this group
of patients with locally advanced disease is likely to improve
target definition.
The potential impact on clinical management is diﬃcult
to assess in a retrospective series and is inevitably subjective
in nature. Only one patient in whom lung metastases were
identified had a clear change in treatment intent/modality. In
the 6 patients in whom FDG PET-CT downclassified nodal
involvement, radiotherapy planning was felt to have been
altered in 3 patients (Table 5); in one of these, the lack of FDG
uptake in an equivocal lymph node allowed unilateral radio-
therapy, whilst in 2 others the downclassified lymph nodes
were treated with prophylactic radiotherapy doses. In 11
of the 14 cases in which an additional lymph node level
was identified by FDG PET-CT (Table 5), this nodal level
was included in the high-dose volume. In 7 of these cases,
FDG PET-CT was felt to have altered the radiotherapy plan.
Therefore, FDG PET-CT appeared to have aﬀected the radio-
therapy planning process with regard to the lymph node
target in a total of 10/55 (18%) patients. This is a higher pro-
portion than in the Lonneux et al. study (8/233 patients)
[32]. This is likely to be due to diﬀerences in themethodology
by which a “change in radiotherapy planning” is defined. For
example, in our series patients in whom an extra nodal level
appears to have been included within the high-dose volume
are classed as a change in radiotherapy planning.
The impact of FDG PET-CT upon T-stage assessment has
not been assessed in this study. Tumour size assessment based
upon FDG PET is highly dependant upon the method of seg-
mentation and no superiority over conventional imaging has
been demonstrated [9].
Refinements in imaging techniques are likely to lead to
further improvements in the results obtained with functional
imaging modalities. The results of FDG-PET-CT imaging are
aﬀected by diﬀering acquisition protocols, image reconstruc-
tion, and interpretation techniques [40]. Standardisation of
these processes will help with the comparison of the results
of multicentre PET/CT series. A dedicated head and neck
FDG PET-CT protocol may oﬀer advantages in the detection
of small lymph node metastases [41]; especially the use of
intravenous contrast will allows the identification of small-
volume and/or necrotic lymph nodes. Studies of novel PET
tracers [16] may bring further improvements. Diﬀusion-
weighted MRI has demonstrated encouraging results in the
assessment of cervical lymph node metastases [42, 43].
5. Conclusion
In this series of patients with locally advanced HNSCC, FDG
PET-CT altered the TNM stage and the identification of lev-
els of nodal involvement in 31% and 40%, respectively. FDG
PET-CT has potentially significant consequences for target
volume definition in the IMRT era. The addition of imag-
ing substudies to ongoing clinical trials will provide the ideal
platform to optimise FDG PET-CT protocols and to further
define a role in the management of HNSCC.
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